Capricor Therapeutics, Inc. (CAPR) Financial Ratios
27 years of historical data (1999–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: 60.87
30Y Low56.8·High60.9
P/B Ratio
↑
4.46
-6% vs avg
5yr avg: 4.74
30Y Low0.4·High24.7
ROE
↑
-46.6%
↓+45% vs avg
5yr avg: -85.2%
30Y Low-408%·High67%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CAPR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Capricor Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.3B | $1.3B | $486M | $131M | $95M | $68M | $53M | $5M | $12M | $42M | $49M |
| Enterprise Value | $1.1B | $1.1B | $476M | $118M | $88M | $36M | $21M | $850752 | $8M | $36M | $60M |
| P/E Ratio → | -12.98 | — | — | — | — | — | — | — | — | 17.56 | — |
| P/S Ratio | — | — | 21.82 | 5.20 | 37.15 | 276.24 | 172.15 | 4.73 | 7.22 | 15.88 | 15.47 |
| P/B Ratio | 4.46 | 4.39 | 3.34 | 5.79 | 8.04 | 2.16 | 1.89 | 0.69 | 2.61 | 3.77 | — |
| P/FCF | — | — | — | — | 60.87 | — | — | — | — | — | — |
| P/OCF | — | — | — | — | 19.28 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CAPR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 21.38 | 4.71 | 34.38 | 145.52 | 67.88 | 0.85 | 4.67 | 13.57 | 18.82 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | 12.79 | — |
| EV / FCF | — | — | — | — | 56.35 | — | — | — | — | — | — |
CAPR Profitability
Margins and return-on-capital ratios measuring operating efficiency
Operating margins have compressed from -95.6% to -191.1% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -46.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | -124.4% | -44.8% | -755.1% | 100.0% | 100.0% | -411.6% | 100.0% | 100.0% | -377.5% |
| Operating Margin | — | — | -191.1% | -95.6% | -1163.9% | -8549.9% | -4412.6% | -769.5% | -917.2% | -482.4% | -532.2% |
| Net Profit Margin | — | — | -181.7% | -88.5% | -1137.4% | -8175.9% | -4401.9% | -760.4% | -909.1% | 91.2% | -589.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -46.6% | -46.6% | -48.2% | -129.6% | -134.5% | -67.2% | -78.0% | -133.4% | -191.8% | 67.3% | — |
| ROA | -39.9% | -39.9% | -35.3% | -41.0% | -63.5% | -52.7% | -59.7% | -75.1% | -119.0% | 13.9% | -108.0% |
| ROIC | -93.0% | -93.0% | -43.8% | -242.6% | -1087.6% | — | — | -351.9% | -422.4% | -163.7% | -275.2% |
| ROCE | -46.1% | -46.1% | -48.1% | -89.2% | -93.2% | -60.8% | -65.4% | -85.0% | -135.7% | -90.4% | -145.1% |
CAPR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $288M exceeds total debt of $21M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.01 | 0.10 | 0.22 | 0.09 | 0.01 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.87 | -0.07 | -0.55 | -0.60 | -1.02 | -1.15 | -0.57 | -0.92 | -0.55 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | -4.52 | — | — | — | — | — | — |
| Interest Coverage | -35.51 | -35.51 | — | — | — | — | — | — | — | 7.10 | -49.26 |
Net cash position: cash ($288M) exceeds total debt ($21M)
CAPR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Capricor Therapeutics, Inc.'s current ratio of 9.01x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.63x to 9.01x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.01 | 9.01 | 7.77 | 1.63 | 1.82 | 8.82 | 11.33 | 11.74 | 6.75 | 9.40 | 3.70 |
| Quick Ratio | 9.01 | 9.01 | 7.77 | 1.63 | 1.82 | 8.82 | 11.33 | 11.74 | 6.75 | 9.40 | 3.70 |
| Cash Ratio | 8.88 | 8.88 | 7.21 | 1.26 | 1.76 | 8.44 | 10.99 | 11.01 | 5.78 | 8.45 | 3.31 |
| Asset Turnover | — | — | 0.13 | 0.43 | 0.05 | 0.01 | 0.01 | 0.09 | 0.18 | 0.16 | 0.17 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 169.93 | 150.36 | 78.33 | 583.87 | 65.88 | 31.95 | 44.75 | 47.18 | 25.55 |
CAPR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Capricor Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | 5.7% | — |
| FCF Yield | — | — | — | — | 1.6% | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $46M | $35M | $27M | $25M | $23M | $16M | $4M | $3M | $3M | $2M |
Peer Comparison
Compare CAPR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CAPRYou | $1B | -13.0 | — | — | — | — | -46.6% | -93.0% | — |
 SRPT | $2B | -2.5 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 CRSP | $5B | -8.4 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 EXEL | $13B | 18.5 | 14.1 | 15.4 | 96.4% | 37.6% | 35.5% | 32.1% | 0.2 |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 RARE | $3B | -5.0 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 EDIT | $274M | -1.6 | — | — | 100.0% | -245.2% | -198.1% | — | — |
 NTLA | $2B | -4.1 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 BEAM | $4B | -43.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 SGMO | $73M | -0.4 | — | — | 80.8% | -273.1% | -2891.8% | -5405.6% | — |
 RCKT | $378M | -1.7 | — | — | — | — | -60.3% | -62.4% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 27 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
CAPR — Frequently Asked Questions
Quick answers to the most common questions about buying CAPR stock.
What is Capricor Therapeutics, Inc.'s P/E ratio?
Capricor Therapeutics, Inc.'s current P/E ratio is -13.0x. The historical average is 17.6x.
What is Capricor Therapeutics, Inc.'s ROE?
Capricor Therapeutics, Inc.'s return on equity (ROE) is -46.6%. The historical average is -137.4%.
Is CAPR stock overvalued?
Based on historical data, Capricor Therapeutics, Inc. is trading at a P/E of -13.0x. Compare with industry peers and growth rates for a complete picture.